Ignite Proteomics (BACK) enters $420K biomarker study with Inova for GI cancers

IMAC Holdings, Inc.

Subsidiary Ignite Proteomics will analyze up to 600 tumor samples using RPPA technology.
Maximum contract value $420,000; $175,000 payable upon execution.
Data on 32+ protein biomarkers including HER2, RET, MHC-II, EGFR, TROP2, AKT, ERK.
Results provided to Inova's Molecular Tumor Board to guide late-stage gastrointestinal cancer therapy.
Agreement expected to contribute meaningfully to Ignite's 2025 revenue.

item 1.01item 2.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.